PT  - JOURNAL ARTICLE
AU  - Arantxa Valdivia
AU  - Ignacio Torres
AU  - Víctor Latorre
AU  - Clara Francés-Gómez
AU  - Eliseo Albert
AU  - Roberto Gozalbo-Rovira
AU  - María Jesús Alcaraz
AU  - Javier Buesa
AU  - Jesús Rodríguez-Díaz
AU  - Ron Geller
AU  - David Navarro
TI  - Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
AID  - 10.1101/2020.09.07.20188151
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.07.20188151
4099  - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20188151.short
4100  - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20188151.full
AB  - Background Whether antibody levels measured by commercially-available enzyme or chemiluminescent immunoassays targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum neutralizing activity remains to be established for many of these assays.Objectives To evaluate the degree of correlation between neutralizing antibodies (NtAb) binding the SARS-CoV-2 Spike (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays in sera drawn from hospitalized COVID-19 patients.Patients and Methods Ninety sera from 51 hospitalized COVID-19 patients were assayed by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG and the COVID-19 ELISA IgG assays.Results Overall, the results obtained with the COVID-19 ELISA IgG test showed the highest agreement with the NtAb assay (κ, 0.85; 95% CI, 0.63-1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG assay (92.2% for both). Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (Rho = 0.73) and moderate for the remaining assays (Rho = 0.48 to 0.59). The kinetic profile of serum NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays.Conclusions The suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Valencian Government grant IDIFEDER/2018/056 to JRD and Covid_19-SCI to RG.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the Research Ethics Committee of Hospital Clinico Universitario INCLIVA (March 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at Hospital Clinico Valencia. Derived data supporting the finding of this study are available from the corresponding author on request